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Background: Despite the fact that thrice-weekly hemodialysis is regarded as the standard for maintenance
dialysis, prescription of twice-weekly hemodialysis with a longer treatment time is common in Hong Kong to
allow more renal failure patients to receive treatment. In an attempt to assess whether clinical and biochemical
parameters differ between hemodialysis with different interdialytic intervals, we investigated the urea kinetics
and blood biochemistry parameters in patients undergoing two dialysis sessions per week.
Methods: Data were collected for 16 anuric stable maintenance dialysis patients for two dialyses in the same
week.
Results: Compared with hemodialysis after a short interdialytic interval (HDSII), hemodialysis after a long inter-
dialytic interval (HDLII) led to significantly greater interdialytic weight gain. Predialysis plasma potassium, urea
and creatinine concentrations were significantly higher for HDLII. On the other hand, there were no significant
differences in predialysis plasma sodium, chloride, total carbon dioxide, albumin, calcium and phosphorus
concentrations and anion gap between HDSII and HDLII. Both immediate postdialysis and 30-minute postdialysis
plasma urea concentrations were significantly higher for HDLII. Urea removal, creatinine removal, modified
urea reduction ratio (mURR), single-pool Kt/V (spKt/V) and equilibrated Kt/V (eKt/V) were significantly
greater for HDLII. Moreover, there was a good linear relationship between mURR for HDSII and HDLII. Similar
findings were noted for both spKt/V and eKt/V. However, there were no differences between the two dialyses
in urea reduction ratio, normalized protein equivalent of total nitrogen appearance and postdialysis urea rebound.
Conclusion: Our findings suggest that there are differences in some dialysis indices and blood biochemistry
parameters between HDSII and HDLII. Standardization of dialysis sessions (HDSII or HDLII) for blood sampling
schedules is needed to permit meaningful comparison of dialysis indices and biochemistry parameters within
and between dialysis patients. [Hong Kong J Nephrol 2004;6(1):43–51]
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INTRODUCTION
Following analysis of the National Cooperative Dialysis
Study, it is agreed that prescription of an adequate hemo-
dialysis dose is important to improve clinical outcome
[1]. It is recommended that standard maintenance hemo-
dialysis should take place three times per week [2,3],
and that the treatment time should be 4 hours per session
[3]. A reduction in dialysis frequency to twice per week is
considered inappropriate unless there is significant resi-
dual renal function [2,3]. Thus, it is not surprising that
the use of twice-weekly hemodialysis in the USA has
decreased from 12.9% to 3.6% for incident hemodialysis
patients (defined as those with a diagnosis of end-stage
renal disease and treated with hemodialysis for less than
12 months [4]) between 1990 and 1996 [5]. Similarly, in
Australia and New Zealand, only 1% to 2% of patients
are treated using two hemodialysis sessions per week
[6]. However, twice-weekly hemodialysis is still common
in some countries. In the UK, for instance, twice-weekly
hemodialysis is used in more than 5% of patients in 38%
of surveyed renal units, and in more than 20% of patients
in 5% of units [7]. In Iran, 42.5% of hemodialysis patients
receive dialysis twice weekly [8]. Similarly, because of
limited availability of hemodialysis facilities in Hong
Kong, it is common to prescribe twice-weekly hemodial-
ysis to allow more patients to be treated. In our centers,
more than 80% of chronic hemodialysis patients are
prescribed a twice-weekly regimen. However, a longer
treatment time (4–5.5 hours) than in the thrice-weekly
regimen is usually prescribed to compensate for the lost
day of treatment [3].
Dialysis units may quantify the hemodialysis dose
and measure the clinical chemistry parameters either
at the beginning-of-the-week or the end-of-the-week
dialysis session for patients on twice-weekly
hemodialysis. However, it should be noted that these
clinical parameters may be affected by the length of
interdialytic interval. Moreover, either session could
be the hemodialysis after a short interdialytic interval
(HDSII) or that after a long interdialytic interval (HDLII).
For instance, Monday could be the HDLII for a Monday/
Thursday schedule, while it is the HDSII for a Monday/
Friday schedule. If there are significant differences in
dialysis indices and clinical chemistry parameters
between the HDSII and HDLII, it will be necessary to stan-
dardize blood sampling schedules to permit meaning-
ful comparisons of data for a single patient over time,
among patients and among different hemodialysis
facilities. Therefore, we undertook the present study to
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investigate whether there were any differences in urea
kinetics and blood biochemistry parameters for the two
dialyses in patients on twice-weekly hemodialysis.
PATIENTS AND METHODS
Patients with end-stage renal disease maintained for
at least 6 months on twice-weekly hemodialysis were
selected from the Dialysis Unit of the Alice Ho Miu
Ling Nethersole Hospital and the Yaumatei Renal
Dialysis Centre of the Queen Elizabeth Hospital.
Patients had to be clinically stable with no change in
dialysis prescription for at least 3 months before
enrollment. The 16 patients, six females and 10 males,
had a mean age of 55 ( 10 years. Seven patients were
on a Monday/Thursday schedule, three were on a
Tuesday/Friday schedule, and six were on a Wednesday/
Saturday schedule. All patients were anuric. Patients
were dialyzed for 4.0–5.5 hours, five using Baxter 550TM
dialysis machines (Baxter Healthcare Corporation,
Deerfield, IL, USA), and 11 using Fresenius 4008BTM
dialysis machines (Fresenius Medical Care, Schwein-
furt, Germany). Dialyzers had a urea clearance of 221–
248 mL/min at a dialyzer blood flow of 300 mL/min
and a dialysate flow of 500 mL/min. During a di-
alysis session, the dialyzer blood flow rate averaged
250 mL/min and the prescribed dialysate flow rate was
maintained at 500 mL/min. In 13 patients, bicarbonate-
based dialysates were used, while in the remaining three
patients, acetate-based dialysates were used.
Patients were dialyzed as usual, maintaining their
types of dialyzer, dialysate, dialyzer blood flow rate,
dialysate flow rate, treatment time, dry weight and
dialysis shift (morning or afternoon) during the entire
study. Two dialysis treatments in the same week (HDSII
and HDLII) were studied. Blood samples drawn before
dialysis from the dry arterial tubing after insertion of
the needle into the vascular access were used for
sodium, potassium, urea, creatinine, total carbon
dioxide, chloride, albumin, calcium and phosphorus
analysis. Two postdialysis blood samples were taken
from the arterial bloodline sampling port for urea
analysis, one at 15 seconds postdialysis when the blood
pump rate had slowed to 50 mL/min for 15 seconds,
and the other 30 minutes after stopping dialysis. A
partial dialysate collection method was used to procure
a representative sample of the total spent dialysate [9,
10]. All dialysate urea concentrations were analyzed
in duplicate.
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Single-pool Kt/V (spKt/V), equilibrated Kt/V
(eKt/V), urea reduction ratio (URR), modified urea reduc-
tion ratio (mURR), normalized protein equivalent of to-
tal nitrogen appearance (nPNA), and postdialysis urea
rebound were calculated [11–14] (equations described
in Appendix A). Results are expressed as median and
interquartile range. Wilcoxon’s signed-rank test was
used to compare clinical and biochemical parameters
for HDSII and HDLII. Correlation between the dialysis
indices of HDSII and HDLII were analyzed using
Pearson’s correlation coefficient. A p value of less than
0.05 was considered statistically significant.
RESULTS
No adverse events were reported during the study. In
particular, there was no intradialytic episode of
hypotension or any event that required interruption or
early termination of dialysis treatment.
Table 1 shows the clinical parameters for the two
dialyses. As expected, the dialysis-free interval before
the HDLII was significantly longer than that before the
HDSII. Interdialytic weight gain was significantly great-
er for HDLII than for HDSII, but this significance
disappeared after adjusting for interdialytic interval.
Predialysis plasma potassium, urea and creatinine
concentrations were significantly higher for HDLII than
for HDSII (Table 2). There were no differences in
predialysis plasma sodium, chloride, total carbon
dioxide, albumin, calcium and phosphorus concen-
trations or anion gap between HDSII and HDLII. The
immediate and 30-minute postdialysis plasma urea
concentrations for HDLII were significantly greater than
those for HDSII. Despite significantly higher predialy-
sis, immediate postdialysis and 30-minute postdialysis
plasma urea concentrations for HDLII, there were no
differences in the ratios of immediate postdialysis to
predialysis plasma or 30-minute postdialysis to pre-
dialysis plasma urea concentrations between the two
dialyses (Table 3). As there was no change in dialysis
prescription, including dry weight, it was not surprising
that the volume of ultrafiltrate was significantly greater
for HDLII to tackle the higher interdialytic weight gain
(Tables 1 and 3).
Table 4 shows the dialysis indices for the two dialy-
ses. The amount of urea and creatinine removed per
dialysis and the mURR, spKt/V and eKt/V for HDLII
Table 1. Clinical parameters for the two dialyses for patients on twice-weekly hemodialysis (n = 16).
HDSII HDLII p
Dialysis-free interval (d) 2.80 (2.74–2.82) 3.81 (3.79–3.83) < 0.0001
Interdialytic weight gain (kg) 1.85 (1.53–2.51) 3.00 (2.37–3.30) 0.0002
Interdialytic weight gain per day (kg/d) 0.67 (0.54–0.92) 0.78 (0.62–0.87) 0.5970
Data are expressed as median (interquartile range). HDSII = hemodialysis after a short interdialytic interval (3-day interval); HDLII =
hemodialysis after a long interdialytic interval (4-day interval).
Table 2. Pre- and postdialysis blood biochemistry for patients on twice-weekly hemodialysis (n = 16).
HDSII HDLII p
Predialysis
Sodium (mmol/L) 137.0 (135.4–138.5) 137.0 (134.7–138.3) 0.426
Potassium (mmol/L) 5.65 (5.22–5.89) 5.95 (5.58–6.21) 0.041
Chloride (mmol/L) 101.0 (99.3–103.1) 99.5 (97.4–102.1) 0.268
Total CO2 (mmol/L) 21.0 (18.8–21.9) 21.5 (18.5–22.8) 0.903
Urea (mmol/L) 32.50 (29.07–35.96) 35.75 (33.29–42.27) 0.0002
Creatinine (+mol/L) 1102.0 (1078.0–1203.0) 1230.5 (1157.2–1350.3) < 0.0001
Albumin (g/L) 40.0 (38.0–41.4) 38.5 (38.0–40.4) 0.600
Calcium (mmol/L) 2.48 (2.34–2.55) 2.42 (2.29–2.52) 0.389
Phosphorus (mmol/L) 2.55 (2.17–2.90) 2.37 (1.93–2.76) 0.421
Anion gap (mEq/L) 15.1 (13.5–17.3) 16.0 (13.2–19.1) 0.542
Immediate postdialysis urea (mmol/L) 8.05 (7.27–10.21) 9.25 (8.14–11.50) 0.0027
30-minute postdialysis urea (mmol/L) 9.55 (8.35–11.50) 10.65 (9.46–13.17) 0.0002
Data are expressed as median (interquartile range). HDSII = hemodialysis after a short interdialytic interval (3-day interval); HDLII =
hemodialysis after a long interdialytic interval (4-day interval); CO2 = carbon dioxide.
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Table 4. Dialysis indices for patients on twice-weekly hemodialysis (n = 16).
HDSII HDLII p
Urea removal (mmol) 825.5 (737.1–907.1) 927.8 (869.8–1105.5) 0.0008
Creatinine removal (mmol) 20.8 (19.2–24.8) 25.2 (22.2–28.5) 0.0003
URR (%) 73.6 (70.5–76.1) 73.8 (71.4–76.9) 0.274
mURR (%) 81.4 (78.0–83.4) 82.4 (79.2–84.7) 0.044
spKt/V 1.67 (1.54–1.80) 1.75 (1.61–1.90) 0.016
eKt/V 1.50 (1.40–1.62) 1.56 (1.45–1.70) 0.025
nPNA (g/kg/d) 1.18 (1.07–1.30) 1.15 (1.07–1.32) 0.528
Postdialysis urea rebound (%) 13.7 (11.1–16.9) 15.6 (13.4–18.1) 0.252
Data are expressed as median (interquartile range). HDSII = hemodialysis after a short interdialytic interval (3-day interval); HDLII =
hemodialysis after a long interdialytic interval (4-day interval); URR = urea reduction ratio; mURR = modified urea reduction ratio;
spKt/V = single-pool Kt/V; eKt/V = equilibrated Kt/V; nPNA = normalized protein equivalent of total nitrogen appearance.
Table 3. Treatment and model parameters for patients on twice-weekly hemodialysis (n = 16).
HDSII HDLII p
R 0.26 (0.24–0.30) 0.26 (0.23–0.29) 0.274
R’ 0.30 (0.28–0.33) 0.30 (0.27–0.33) 0.706
Postdialysis body weight (kg) 51.0 (48.2–56.3) 50.9 (48.1–56.3) 0.176
Volume of ultrafiltrate (L) 2.60 (2.43–3.34) 3.70 (3.05–3.96) 0.0003
Data are expressed as median (interquartile range). HDSII = hemodialysis after a short interdialytic interval (3-day interval); HDLII =
hemodialysis after a long interdialytic interval (4-day interval); R = immediate postdialysis plasma urea to predialysis plasma urea ratio;
R’ = 30-minute postdialysis plasma urea to predialysis plasma urea ratio.
were significantly greater than those for HDSII. There
was a strong linear correlation for mURR between the
two dialyses (Figure 1). Similarly, there was a strong
linear correlation between the two dialyses for Kt/V
levels (both spKt/V and eKt/V) (Figures 2 and 3).
However, there were no differences in URR and nPNA
Figure 1. Correlation between modified urea reduction ratio (mURR)
for hemodialysis after a short interdialytic interval (HDSII) and that for
hemodialysis after a long interdialytic interval (HDLII). The solid line
is the regression line and the dashed line is the line of identity.
Figure 2. Correlation between urea single-pool Kt/V (spKt/V) for
hemodialysis after a short interdialytic interval (HDSII) and that for
hemodialysis after a long interdialytic interval (HDLII). The solid line
is the regression line and the dashed line is the line of identity.
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Figure 3. Correlation between urea equilibrated Kt/V (eKt/V) for
hemodialysis after a short interdialytic interval (HDSII) and that
for hemodialysis after a long interdialytic interval (HDLII). The
solid line is the regression line and the dashed line is the line of
identity.
dialysis. There was a significantly greater interdialy-
tic weight gain for HDLII than for HDSII, but the differ-
ence was no longer significant after adjusting for
interdialytic interval. This suggests that patients might
not adjust their dietary fluid intake in the long
interdialytic interval. There were also significantly
higher predialysis concentrations of plasma potassium,
urea and creatinine for HDLII. The differences in
predialysis blood biochemistry appear to be related to
the longer interdialytic interval and effect of dietary
intake. Another factor that might influence predialysis
blood biochemistry is the time of day of the dialysis.
Predialysis plasma potassium concentrations increased
progressively for patients dialyzed later in the day
compared with earlier dialysis shifts [15]. However,
this factor might not be relevant because all patients
kept their dialysis shifts unchanged during the study.
There were significant differences in some but not
all dialysis indices between HDSII and HDLII. These
discrepancies could be explained by the way the indices
are derived. The absolute values of pre- and postdialy-
sis plasma urea concentrations are not required in the
calculation of URR, which is estimated by the ratio of
post- to predialysis plasma urea [12]. Our results show
that, despite higher pre- and postdialysis plasma urea
concentrations for HDLII, there was no difference in the
ratio of post- to predialysis plasma urea between the
two dialyses. Hence, it is not surprising that there was
no difference in URR between HDSII and HDLII. In
contrast to URR, mURR and Kt/V consider the effects
of ultrafiltration and intradialytic urea generation [11,
13]. Apart from the ratio of post- to predialysis plasma
urea, estimations of mURR and Kt/V (both spKt/V and
eKt/V) require input of dialysis session length, ultra-
filtrate volume and postdialysis body weight. The higher
mURR and Kt/V values for HDLII were primarily a
reflection of the greater ultrafiltrate volume for HDLII,
which is the only parameter that was significantly
different between the two dialyses (Table 3). Based on
our findings, the difference in Kt/V values between the
two dialyses will be exaggerated for patients with a
small post- to predialysis plasma urea ratio and for
patients with big differences in ultrafiltrate volume
between the dialyses (Appendix B).
It is well known that hemodialysis treatment time
affects solute removal and, hence, blood biochemistry.
Moreover, a difference in the treatment time without a
change in dialysis frequency unavoidably affects the
interdialytic interval. For instance, a longer treatment
time will be associated with a shorter dialysis-free
interval. Thus, it is possible that the treatment time
might also have an effect on urea kinetics and
biochemistry parameters. Our data suggest that the
treatment time might affect the relationship of clinical
parameters between HDSII and HDLII,  but the
discrepancy between the findings in the two groups
levels between HDSII and HDLII. No difference was
noted in the postdialysis urea rebound between the two
dialyses.
To evaluate the effect of dialysis treatment time on
urea kinetics and clinical chemistry, the data were
further categorized according to treatment time (Table
5). Within each group, clinical parameters were
compared for HDSII and HDLII. In both groups, the
predialysis plasma urea and creatinine and 30-minute
postdialysis plasma urea concentrations were signi-
ficantly greater for HDLII compared with HDSII. In
contrast to patients dialyzed for the longer treatment
time, patients treated for the short time demonstrated
no significant differences in interdialytic weight gain,
predialysis plasma potassium, volume of ultrafiltrate,
urea removal, creatinine removal, mURR, spKt/V and
eKt/V between HDSII and HDLII. Among patients treated
for the longer time, there was no significant difference
in the immediate postdialysis plasma urea concentration
between HDSII and HDLII.
DISCUSSION
These results suggest that there are significant dif-
ferences in certain clinical parameters, blood bio-
chemistry parameters and dialysis indices between
HDSII and HDLII for patients on twice-weekly hemo-
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Table 5. Clinical parameters for patients on twice-weekly hemodialysis according to treatment time and interdialytic interval.
Treatment time*
4–4.5 hr/session (n = 7) 5–5.5 hr/session (n = 9)
HDSII HDLII HDSII HDLII
Dialysis-free interval (d) 2.81 3.83† 2.79 3.80†
Interdialytic weight gain (kg) 1.90 3.00 1.80 2.60†
Interdialytic weight gain per day (kg/d) 0.69 0.78 0.64 0.68
Predialysis
Sodium (mmol/L) 137.0 137.0 137.0 136.0
Potassium (mmol/L) 6.00 5.50 5.50 6.00†
Chloride (mmol/L) 99.0 101.0 101.0 98.0
Total CO2 (mmol/L) 21.0 22.0 20.5 20.9
Urea (mmol/L) 36.30 36.10† 29.60 34.80†
Creatinine (+mol/L) 1076.0 1150.0† 1204.0 1292.0†
Albumin (g/L) 39.0 38.0 41.0 40.0
Calcium (mmol/L) 2.50 2.39 2.47 2.42
Phosphorus (mmol/L) 2.40 2.18 2.60 2.51
Anion gap (mEq/L) 16.0 16.0 15.1 14.0
Immediate postdialysis urea (mmol/L) 9.90 11.90† 6.60 7.80
30-minute postdialysis urea (mmol/L) 11.00 13.30† 7.70 9.40†
R 0.30 0.30 0.25 0.23
R’ 0.33 0.34 0.28 0.25
Postdialysis body weight (kg) 50.5 50.5 52.7 52.2
Volume of ultrafiltrate (L) 2.70 3.80 2.50 3.60†
Urea removal (mmol) 824.7 916.8 826.3 938.9†
Creatinine removal (mmol) 20.7 19.9 22.5 25.6†
URR (%) 70.0 70.4 74.8 77.5
mURR (%) 78.1 79.3 82.1 84.6†
spKt/V 1.54 1.61 1.73 1.85†
eKt/V 1.39 1.43 1.55 1.72†
nPNA (g/kg/d) 1.30 1.14 1.16 1.17
Postdialysis urea rebound (%) 11.7 14.3 15.1 19.0
Data are expressed as median. HDSII = hemodialysis after a short interdialytic interval (3-day interval); HDLII = hemodialysis after a long
interdialytic interval (4-day interval); CO2 = carbon dioxide; R = immediate postdialysis plasma urea to predialysis plasma urea ratio;
R’ = 30-minute postdialysis plasma urea to predialysis plasma urea ratio; URR = urea reduction ratio; mURR = modified urea reduction
ratio; spKt/V = single-pool Kt/V; eKt/V = equilibrated Kt/V; nPNA = normalized protein equivalent of total nitrogen appearance. *The
small numbers may prevent detection of statistically significant differences because of a lack of power. †p < 0.05, HDSII vs HDLII.
could also be related to the small sample size of the
subgroup analysis. Further study is needed to re-
evaluate this.
Our findings have several potential implications
for the care of patients on twice-weekly hemodialysis.
Patients on hemodialysis are prone to develop fluid
overload and hyperkalemia because of kidney failure.
Our data showed that there were mean differences of
0.81 kg in interdialytic weight gain and of 0.33 mmol/L
in predialysis plasma potassium between HDSII and
HDLII. These differences may be clinically significant
for patients who are on the verge of developing fluid
overload or hyperkalemia. Patients should be advised
to pay extra attention to dietary compliance, especially
in the long interdialytic interval. The dialysis schedule
for patients on twice-weekly hemodialysis could be
Monday/Thursday, Monday/Friday, Tuesday/Friday,
Tuesday/Saturday or Wednesday/Saturday. If in-
creasing dialysis frequency is deemed impossible or
unfeasible, it is not advisable to put patients with a
history of recurrent heart failure or hyperkalemia on a
Monday/Thursday schedule in dialysis centers where
service is not available on Sunday because these patients
are prone to develop fluid overload and hyperkalemia
on Sunday (i.e. the day before the scheduled HDLII on
Monday).
For patients on thrice-weekly hemodialysis, it is
recommended that the dialysis dose be estimated at the
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midweek dialysis session [2,3]. However, there is no
established consensus on which dialysis session should
be used to measure dialysis dose for patients on twice-
weekly hemodialysis. Our results substantiate the need
to standardize the blood-sampling schedule because
there were significant differences in some dialysis
indices between the two dialyses. Although the
differences might be small (mean differences of 1.3%
in mURR, 0.08 in spKt/V values, and 0.06 in eKt/V
levels between the two dialyses), standardization of
dialysis session for hemodialysis dose quantification
is necessary to allow reliable and valid comparison of
adequacy of dialysis parameters within and between
end-stage renal disease patients and clinical trials.
Equations describing the mathematical relationship in
mURR, spKt/V and eKt/V between HDLII and HDSII
were derived by linear regression analysis (Figures 1–
3). These simple equations may be useful in quality-
assurance programs or in epidemiologic studies to
adjust for the effect of interdialytic interval on dialysis
indices when only limited data concerning dialysis
treatment are available. Finally, the present study was
not designed to assess which dialysis session should
be used to quantify the dialysis dose. However, in view
of the fact that a higher predialysis plasma potassium
concentration was found for HDLII, we suggest that the
routine blood sampling for quantification of dialysis
dose and predialysis blood biochemistry monitoring
be standardized on HDLII. This arrangement may help
to identify patients who are at risk of developing
hyperkalemia so that early intervention can be given.
The present study has some limitations. First, the
sample size is small, which may prevent the detection
of statistically significant differences in some clinical
parameters because of a lack of power. Second, the
patients recruited were anuric and extrapolation of the
results to patients with significant urine output should
be undertaken with caution. Residual renal function
could affect blood biochemistry, interdialytic weight
gain and, hence, ultrafiltrate volume.
In conclusion, our data suggest that there may be
differences in some clinical parameters, blood biochem-
istry parameters and dialysis indices between HDSII and
HDLII for patients on twice-weekly hemodialysis. The
findings may help in the design of dialysis and blood-
sampling schedules to identify patients who are at risk
of developing hyperkalemia. They also substantiate the
need to standardize the schedule for dialysis dose estima-
tion to allow meaningful comparison of dialysis indices
within and between end-stage renal disease patients.
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Appendix A
Meaning of symbols
BW Postdialysis body weight, kg
c Creatinine concentration in the spent dialysate, mmol/L
C1 Predialysis plasma urea, mmol/L
C2 Postdialysis plasma urea, obtained at the end of dialysis after having slowed down the blood pump rate to
   50 mL/min for 15 seconds, mmol/L
C3 Equilibrated postdialysis plasma urea, obtained 30 minutes after termination of hemodialysis, mmol/L
Creat Creatinine removed by dialysis, mmol
Qd Dialysate flow rate, L/hr
R C2/C1
R’ C3/C1
t Dialysis session length, hr
u Urea concentration in the spent dialysate, mmol/L
U Urea removed by dialysis, mmol
UF Volume of ultrafiltrate, L
Calculation of urea and creatinine removal by direct quantification method [9,10]
U = u(Qd = t + UF)
Creat = c(Qd = t + UF)
Calculation of postdialysis urea rebound (PDUR)
PDUR = [(C3 – C2)/C2] = 100%
Calculation of URR [12]
URR = (1 – R) = 100%
Calculation of mURR [13]
mURR = {1 – [R/(1 + 2UF/BW)] + 0.01t] = 100%
Calculations of Kt/V [11]
spKt/V = –ln(R – 0.008t) + (4 – 3.5R) = UF/BW
eKt/V = –ln(R’ – 0.008t) + (4 – 3.5R’) = UF/BW
Calculation of nPNA [14]
nPNA (HDSII) = {C1 = 2.8/[33 + 3.6 = spKt/VSII + 83.2/(spKt/VSII)]} + 0.168
nPNA (HDLII) = {C1 = 2.8/[48 + 5.14 = spKt/VLII + 79/(spKt/VLII)]} + 0.168
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Equations to estimate Kt/V values for HDSII and HDLII can be expressed as follows:
Kt/VSII = –ln(RSII – 0.008tSII) + (4 – 3.5RSII)(UF/BW)SII
Kt/VLII = –ln(RLII – 0.008tLII) + (4 – 3.5RLII)(UF/BW)LII
where Kt/VSII and Kt/VLII are the Kt/V values of HDSII and HDLII, respectively. RSII and RLII are the ratios of
postdialysis plasma urea to predialysis plasma urea of HDSII and HDLII, respectively. tSII and tLII are the dialysis
session lengths of HDSII and HDLII, respectively. The (UF/BW)SII and the (UF/BW)LII are the ratios of ultrafiltrate
volume to postdialysis body weight of HDSII and HDLII, respectively.
tSII and tLII are equal as there is no change in dialysis prescription. In addition, our data suggest that there was no
significant difference between RSII and RLII.
Thus, the equation can be rearranged as follows:
Kt/VLII – Kt/VSII = (4 – 3.5R)[(UF/BW)LII – (UF/BW)SII]
From this equation, it can be recognized that the difference between Kt/VSII and Kt/VLII will be exaggerated for
the patient with a small R (ratio of postdialysis plasma urea to predialysis plasma urea), and for the patient with
a big difference in the ultrafiltrate volume between the 2 dialyses.
